AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 16404566
Drug: Direct radiography
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct radiography (DR) at reduced dose
Trial: 28752433
Drug: ANF-RHO (5-50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ANF-RHO (5-50 μg/kg)
Trial: 28752433
Drug: ANF-RHO (5-30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ANF-RHO (5-30 μg/kg)
Trial: 28752433
Drug: ANF-RHO (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ANF-RHO (50 μg/kg)
Trial: 28752433
Drug: Pegfilgrastim (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegfilgrastim (6 mg, equivalent to 80-100 μg/kg)
Trial: 28101914
Drug: Low cortisol
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low cortisol (300 ng mL-1)
Trial: 28101914
Drug: High cortisol
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High cortisol (1,000 ng mL-1)
Trial: 28101914
Drug: Control (0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (0 ng mL-1)
Trial: 25252663
Drug: Passive tactile
RxNorm normalized name: RESPIRATORY TUBE 22MM PASSIVE R#1147378
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Passive tactile stimulation (two daily sessions of 30 minutes each for six months)
Trial: 20181361
Drug: LI160 (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LI160 (600 mg)
Trial: 8347969
Drug: Saline injection
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline injection into the epidural space
Trial: 3519043
Drug: Urapidil 60
RxNorm normalized name: urapidil 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urapidil 60 mg
Trial: 3519043
Drug: Urapidil 90
RxNorm normalized name: urapidil 90 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urapidil 90 mg
Trial: 3519043
Drug: Urapidil 120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urapidil 120 mg
Trial: 29898059
Drug: Ketoprofen 200
RxNorm normalized name: ketoprofen 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoprofen 200 mg + Omeprazole 20 mg (once daily - q.d.)
Trial: 29898059
Drug: Ketoprofen 100
RxNorm normalized name: ketoprofen 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoprofen 100 mg (twice daily - b.i.d.)
Trial: 19459752
Drug: Camel milk
RxNorm normalized name: MILK
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Camel milk (500 mL daily)
Trial: 19459752
Drug: Usual management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual management (diet, exercise, and insulin)
Trial: 17257536
Drug: Sodium hyaluronate
RxNorm normalized name: sodium hyaluronate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium hyaluronate (1.0 ml)
Trial: 17257536
Drug: Triamcinolone acetonide
RxNorm normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triamcinolone acetonide (1.0 ml)
Trial: 11666117
Drug: TTFCA (tablets,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TTFCA (tablets, 60 mg, twice daily for 8 weeks)
Trial: 9840297
Drug: Enzyme-linked immunosorbent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enzyme-linked immunosorbent assay (ELISA) for detecting serum anti-H. pylori immunoglobulin G antibodies
Trial: 31784559
Drug: L-DOPA treatment
RxNorm normalized name: α-methyl-L-dopa
DrugBank: Methyldopa (DB00968)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L-DOPA treatment
Trial: 23707162
Drug: Attenuated Listeria
RxNorm normalized name: Live-attenuated listeria monocytogenes encoding egfrviii-mesothelin vaccine jnj-64041757
DrugBank: Pemlimogene merolisbac (DB16286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Attenuated Listeria monocytogenes vaccine strain with cholera toxin adjuvant
Trial: 20008225
Drug: Intensive chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive chemotherapy as post-remission therapy
Trial: 20008225
Drug: New and
RxNorm normalized name: AVOBENZONE 30 mg in 1 mL / HOMOSALATE 27 mg in 1 mL / OCTISALATE 50 mg in 1 mL / OCTOCRYLENE 50 mg in 1 mL TOPICAL LOTION [Loreal Paris Age Perfect Rosy Tone SPF 30 Renew and revive healthy tone Visibly younger-looking skin]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New and targeted agents
Trial: 17307760
Drug: Congruent odor
RxNorm normalized name: Odor Eaters
DrugBank: Tolnaftate (DB00525)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Congruent odor (e.g., strawberry/sweet)
Trial: 17307760
Drug: Incongruent odor
RxNorm normalized name: Odor Eaters
DrugBank: Tolnaftate (DB00525)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Incongruent odor (e.g., strawberry/sour)
Trial: 15568526
Drug: Sequential Circumferential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential Circumferential Compression Device (SCD)
Trial: 9347373
Drug: Intratracheal furosemide
RxNorm normalized name: Furosemide
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intratracheal furosemide (0.5 mg/kg)
Trial: 8478839
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of both (n = 10)
Trial: 29329559
Drug: Structured process
RxNorm normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structured process to simplify medication administration using the Medication Regimen Simplification Guide for Residential Aged Care.
Trial: 10533448
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy after curative resection
Trial: 15278664
Drug: Vecuronium 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vecuronium 0.1 mg.kg(‐1)
Trial: 15278664
Drug: Vecuronium 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vecuronium 0.2 mg.kg(‐1)
Trial: 6628500
Drug: Moclobemide 100
RxNorm normalized name: moclobemide 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moclobemide 100 mg
Trial: 12665046
Drug: Moclobemide 150
RxNorm normalized name: moclobemide 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moclobemide 150 mg
Trial: 6628500
Drug: Chronic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chronic treatment with optimal therapeutic dose (100-400 mg)
Trial: 30680643
Drug: Proprioceptive Neuromuscular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proprioceptive Neuromuscular Facilitation (PNF) treatment
Trial: 30680643
Drug: Positioning treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Positioning treatment (control)
Trial: 27391237
Drug: Group therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group therapy (20 weeks of manualized therapy)
Trial: 23402870
Drug: γ-tocopherol (γT)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: γ-tocopherol (γT) treatment
Trial: 23402870
Drug: Placebo (sunflower
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (sunflower oil capsule)
Trial: 11978685
Drug: Biphasic human
RxNorm normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Biphasic human insulin 30 (BHI 30)
Trial: 18370539
Drug: Imiquimod 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imiquimod 1% cream
Trial: 6896301
Drug: AVC plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AVC plus tamoxifen (Adriamycin 40 mg/m2 i.v., vincristin 1 mg/m2 i.v. on day 1, cyclophosphamide 200 mg/m2 p.o. on days 3-6, and tamoxifen 20 mg twice daily)
Trial: 6896301
Drug: AVC (Adriamycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AVC (Adriamycin 40 mg/m2 i.v., vincristin 1 mg/m2 i.v. on day 1, cyclophosphamide 200 mg/m2 p.o. on days 3-6)
Trial: 30587515
Drug: Non-users of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-users of aspirin
Trial: 30185394
Drug: BZF961 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BZF961 500 mg BID for 3 days
Trial: 30185394
Drug: BZF961 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BZF961 50 mg QD or BID with ritonavir
Trial: 30185394
Drug: BZF961 lower-dose
RxNorm normalized name: Calendula Flower
DrugBank: Calendula officinalis flower (DB14263)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BZF961 lower-dose regimens
Trial: 25286175
Drug: CIT-S (Culturally
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CIT-S (Culturally Informed Therapy for Schizophrenia), 15 sessions
Trial: 20044810
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose ursodeoxycholic acid
Trial: 3533087
Drug: Suprofen 300
RxNorm normalized name: Suprofen
DrugBank: Suprofen (DB00870)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Suprofen 300 mg suppositories, rectally, t.i.d., for 10 days
Trial: 26496648
Drug: Paromomycin Intramuscular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paromomycin Intramuscular Injection (PMIM) at 11 mg/kg once daily for 21 days
Trial: 26496648
Drug: Paromomycin Intramuscular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paromomycin Intramuscular Injection (PMIM)
Trial: 21852344
Drug: Modified 'You
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified 'You Make the Difference' programme over six weekly sessions
Trial: 20027367
Drug: Tenoten (anxiolytic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tenoten (anxiolytic preparation)
Trial: 11454075
Drug: Nandrolone decanoate
RxNorm normalized name: Nandrolone Decanoate
DrugBank: Nandrolone decanoate (DB08804)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nandrolone decanoate (ND) 100 mg/fortnight
Trial: 11454075
Drug: Megestrol acetate
RxNorm normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Megestrol acetate (MA) 400 mg/day
Trial: 25646326
Drug: Low α-tocopherol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low α-tocopherol (<12.0 μmol/L)
Trial: 25646326
Drug: Low γ-tocopherol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low γ-tocopherol (<0.81 μmol/L)
Trial: 17225981
Drug: Low-dose IL-2
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose IL-2 treatment
Trial: 17225981
Drug: Control (surgery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (surgery without treatment)
Trial: 15129930
Drug: Low carbohydrate
RxNorm normalized name: Low carbohydrate beer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low carbohydrate diet (L-CHO)
Trial: 11411657
Drug: rhuEPO therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhuEPO therapy
Trial: 7985596
Drug: OPC-18790 (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OPC-18790 (mean dose 5.9 +/- 3.5 mg)
Trial: 2465533
Drug: Continuous subcutaneous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous subcutaneous morphine infusion (5-48 mg, median 19 mg daily)
Trial: 2465533
Drug: Conventional intermittent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional intermittent oral or subcutaneous morphine application (10-90 mg, median 50 mg daily)
Trial: 2465533
Drug: Continuous subcutaneous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous subcutaneous morphine infusion
Trial: 2465533
Drug: Long-term continuous
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term continuous subcutaneous morphine infusion
Trial: 28185141
Drug: Faster aspart
RxNorm normalized name: aspartate
DrugBank: Potassium aspartate (DB15819)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Faster aspart (0.2 U/kg) administered subcutaneously in the abdomen
Trial: 28185141
Drug: Faster aspart
RxNorm normalized name: aspartate
DrugBank: Potassium aspartate (DB15819)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Faster aspart (0.2 U/kg) administered subcutaneously in the upper arm
Trial: 28185141
Drug: Faster aspart
RxNorm normalized name: aspartate
DrugBank: Potassium aspartate (DB15819)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Faster aspart (0.2 U/kg) administered subcutaneously in the thigh
Trial: 28185141
Drug: Faster aspart
RxNorm normalized name: aspartate
DrugBank: Potassium aspartate (DB15819)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Faster aspart (0.02 U/kg) administered intravenously
Trial: 23047989
Drug: Acetaminophen (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen (15 mg/kg [160 mg/mL])
Trial: 21778605
Drug: Acetone+Bonding agent
RxNorm normalized name: Acetone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetone+Bonding agent
Trial: 21778605
Drug: Silane+Bonding agent
RxNorm normalized name: silane
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silane+Bonding agent
Trial: 16426088
Drug: Antidepressant exposure
RxNorm normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant exposure (initiation or dose increase)
Trial: 16426088
Drug: Antidepressant exposure
RxNorm normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant exposure (initiation)
Trial: 16426088
Drug: Increased antidepressant
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased antidepressant exposure
Trial: 15010373
Drug: High-dose interferon-alfa
RxNorm normalized name: Interferon Alfa-2A
DrugBank: Interferon alfa-2a (DB00034)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose interferon-alfa (5 MIU/m(2) daily)
Trial: 15010373
Drug: Low-dose interferon-alfa
RxNorm normalized name: Interferon Alfa-2A
DrugBank: Interferon alfa-2a (DB00034)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose interferon-alfa (3 MIU, 5 times a week)
Trial: 9139661
Drug: Three-drug treatment
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-drug treatment with viral protease and reverse transcriptase inhibitors
Trial: 1662579
Drug: Vitamin C,
RxNorm normalized name: Vitamin C, sodium salt
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C, thiopronine, and glutathione at a dose of 12 mmol
Trial: 7037156
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy with methyl‐CCNU and 5‐FU
Trial: 14742344
Drug: Group H
RxNorm normalized name: Prostaglandin group H
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group H (hypnotic anaesthesia) with propofol effect-site concentration maintained at 2.4 microg x ml(‐1)
Trial: 14742344
Drug: Group O
RxNorm normalized name: plasma, human, blood group O
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group O (opioid anaesthesia) with propofol effect-site concentration maintained at 1.2 microg x ml(‐1)
Trial: 11356779
Drug: Testosterone (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone (200 mg im weekly)
Trial: 9578508
Drug: Growth Hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth Hormone (GH) treatment at a dose of 9.5 microg/kg, administered subcutaneously every evening
Trial: 17023701
Drug: Sterol Bev
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterol Bev (orange juice with 1 g plant sterols per 240 mL, twice a day for 8 weeks)
Trial: 17023701
Drug: Placebo Bev
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Bev (reduced-calorie orange juice without plant sterols, twice a day for 8 weeks)
Trial: 15124555
Drug: Standard whole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard whole breast irradiation followed by a tumor bed booster dose
Trial: 10952094
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg isoflavones/kg body weight/day (65 mg/day)
Trial: 10952094
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg isoflavones/kg body weight/day (132 mg/day)
Trial: 10952094
Drug: 0.1 mg
RxNorm normalized name: biotin 0.1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg isoflavones/kg body weight/day (control diet)
Trial: 29800546
Drug: Eradication therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eradication therapy (oral omeprazole 20 mg, amoxicillin 1 g, and clarithromycin 500 mg twice daily for a week)
Trial: 29800546
Drug: No H
RxNorm normalized name: Leader No Hurt Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No H pylori treatment (control group)
Trial: 24491077
Drug: Systemic Behavior
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic Behavior Family Therapy (SBFT)
Trial: 14744173
Drug: Nondirective Supportive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nondirective Supportive Therapy (NST)
Trial: 21443815
Drug: Higher-dose DHA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher-dose DHA (approximately 1 % dietary fatty acids)
Trial: 21443815
Drug: Higher-dose DHA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher-dose DHA
Trial: 17190110
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose (200 mg/d ellagic acid)
Trial: 17190110
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose (100 mg/d ellagic acid)
Trial: 17190110
Drug: Control (0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (0 mg/d ellagic acid: placebo)
Trial: 8706775
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg daily for 2 weeks
Trial: 8719186
Drug: Norepinephrine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norepinephrine infusion (0.1 microgram.kg‐1.min‐1) in groups 2 and 4 (each n = 10)
Trial: 6367888
Drug: Sulphamethoxazole‐trimethoprim (SMX‐TMP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulphamethoxazole‐trimethoprim (SMX‐TMP) (sulphamethoxazole 1600 mg plus trimethoprim 320 mg) four tablets twice daily for two days
Trial: 31055791
Drug: Mycophenolic acid
RxNorm normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mycophenolic acid (1.4 ± 0.5 g/day, as mycophenolate mofetil)
Trial: 31055791
Drug: Tacrolimus (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tacrolimus (5 ± 3 mg/day, immediate release)
Trial: 24639106
Drug: Epidural butorphanol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural butorphanol (1 mg loading dose followed by 48-h infusion of 0.004 % butorphanol with 0.1 % bupivacaine at 2 mL/h)
Trial: 24639106
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline combined with bupivacaine (saline loading dose and 0.1 % bupivacaine infusion at 2 mL/h)
Trial: 24021938
Drug: Guided breathing
RxNorm normalized name: cetylpyridinium chloride Mouthwash [Breath-Away]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guided breathing (12-min sessions daily for 8 weeks)
Trial: 24021938
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care alone (including non-pharmacological and pharmacological treatment)
Trial: 12610036
Drug: Alpha-lipoic acid
RxNorm normalized name: Alpha-lipoic acid
DrugBank: Lipoic acid (DB00166)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha-lipoic acid (ALA) 600 mg, infused daily intravenously for 5 days/week for 14 treatments
Trial: 12610036
Drug: Placebo, infused
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, infused daily intravenously for 5 days/week for 14 treatments
Trial: 25443384
Drug: TXA irrigation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TXA irrigation with normal saline (1 mg/mL)
Trial: 25421903
Drug: Nasal oxygen
RxNorm normalized name: TUBE,NASAL OXYGEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal oxygen therapy
Trial: 8370131
Drug: Melatonin 2
RxNorm normalized name: melatonin 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin 2 mg administered at 1600 and 2000 h
Trial: 3529744
Drug: Drug therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug therapy only (group B)
Trial: 3529744
Drug: Plasmaexchange therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasmaexchange therapy
Trial: 31678222
Drug: Robot-assisted arm
RxNorm normalized name: ARM-210
DrugBank: ARM-210 (DB16944)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Robot-assisted arm therapy and hand functional electrical stimulation (RAT+FES)
Trial: 31678222
Drug: Intensive conventional
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive conventional therapy
Trial: 22894640
Drug: Omega-3 fatty
RxNorm normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 fatty acids (640 mg t.i.d during chemotherapy with paclitaxel and one month after)
Trial: 16371893
Drug: Usual primary
RxNorm normalized name: Sodium primary phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual primary healthcare treatment
Trial: 12208703
Drug: Conventional systemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional systemic medical therapy
Trial: 10342702
Drug: Two doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses of measles vaccine at 6 and 9 months
Trial: 10342702
Drug: One dose
RxNorm normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One dose of inactivated polio vaccine (IPV) at 6 months and measles vaccine at 9 months